Insider Transactions in Q4 2025 at Galectin Therapeutics Inc (GALT)
Insider Transaction List (Q4 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 23
2025
|
Kary Eldred |
BUY
Open market or private purchase
|
Direct |
1,400
+1.06%
|
$4,200
$3.73 P/Share
|
|
Dec 23
2025
|
Kevin D Freeman |
BUY
Open market or private purchase
|
Direct |
5,500
+9.05%
|
$16,500
$3.55 P/Share
|
|
Dec 17
2025
|
Harold H. Shlevin |
SELL
Open market or private sale
|
Direct |
24,499
-52.92%
|
$171,493
$7.04 P/Share
|
|
Dec 17
2025
|
Harold H. Shlevin |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+39.06%
|
$20,000
$1.98 P/Share
|
|
Dec 17
2025
|
Khurram Jamil Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
19,442
-100.0%
|
$136,094
$7.04 P/Share
|
|
Dec 17
2025
|
Khurram Jamil Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,963
+50.0%
|
$29,926
$2.35 P/Share
|
|
Dec 17
2025
|
Joel Lewis President and CEO |
SELL
Open market or private sale
|
Direct |
7,829
-0.93%
|
$54,803
$7.06 P/Share
|
|
Dec 17
2025
|
Joel Lewis President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,829
+0.92%
|
$15,658
$2.86 P/Share
|
|
Dec 16
2025
|
10 X Fund, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
30,681
-0.54%
|
$184,086
$6.66 P/Share
|
|
Dec 15
2025
|
Harold H. Shlevin |
SELL
Open market or private sale
|
Direct |
8,417
-42.89%
|
$50,502
$6.3 P/Share
|
|
Dec 15
2025
|
Harold H. Shlevin |
BUY
Exercise of conversion of derivative security
|
Direct |
8,417
+30.02%
|
$33,668
$4.16 P/Share
|
|
Dec 12
2025
|
Harold H. Shlevin |
SELL
Open market or private sale
|
Direct |
19,793
-63.85%
|
$118,758
$6.27 P/Share
|
|
Dec 12
2025
|
Harold H. Shlevin |
BUY
Exercise of conversion of derivative security
|
Direct |
19,793
+38.97%
|
$79,172
$4.16 P/Share
|
|
Dec 09
2025
|
Harold H. Shlevin |
SELL
Open market or private sale
|
Direct |
16,790
-59.97%
|
$100,740
$6.27 P/Share
|
|
Dec 09
2025
|
Harold H. Shlevin |
BUY
Exercise of conversion of derivative security
|
Direct |
16,790
+37.49%
|
$67,160
$4.16 P/Share
|
|
Dec 08
2025
|
Harold H. Shlevin |
SELL
Open market or private sale
|
Direct |
159,000
-62.73%
|
$795,000
$5.98 P/Share
|
|
Dec 08
2025
|
Harold H. Shlevin |
BUY
Exercise of conversion of derivative security
|
Direct |
155,000
+40.7%
|
$155,000
$1.98 P/Share
|
|
Dec 03
2025
|
10 X Fund, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
120,000
-2.07%
|
$600,000
$5.73 P/Share
|
|
Dec 02
2025
|
10 X Fund, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
30,000
-0.51%
|
$150,000
$5.47 P/Share
|
|
Nov 24
2025
|
10 X Fund, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
24,000
-0.42%
|
-
|
|
Nov 18
2025
|
Jack W Callicutt Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
46,310
-74.6%
|
$277,860
$6.22 P/Share
|
|
Nov 18
2025
|
Jack W Callicutt Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
46,310
+42.69%
|
$46,310
$1.55 P/Share
|
|
Nov 18
2025
|
Joel Lewis President and CEO |
SELL
Open market or private sale
|
Direct |
6,783
-0.81%
|
$40,698
$6.15 P/Share
|
|
Nov 18
2025
|
Joel Lewis President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,783
+0.8%
|
$13,566
$2.39 P/Share
|
|
Nov 17
2025
|
Jack W Callicutt Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
31,610
-50.41%
|
$189,660
$6.03 P/Share
|
|
Nov 17
2025
|
Jack W Callicutt Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
31,610
+32.21%
|
$31,610
$1.44 P/Share
|
|
Nov 17
2025
|
Joel Lewis President and CEO |
SELL
Open market or private sale
|
Direct |
15,680
-1.85%
|
$94,080
$6.04 P/Share
|
|
Nov 17
2025
|
Joel Lewis President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,680
+1.81%
|
$31,360
$2.39 P/Share
|
|
Nov 13
2025
|
Khurram Jamil Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
121,117
-85.48%
|
$605,585
$5.47 P/Share
|
|
Nov 13
2025
|
Khurram Jamil Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
99,250
+46.27%
|
$99,250
$1.98 P/Share
|
|
Nov 11
2025
|
10 X Fund, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
40,000
-0.68%
|
$200,000
$5.25 P/Share
|
|
Nov 10
2025
|
Jack W Callicutt Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,291
-18.8%
|
$31,746
$6.03 P/Share
|
|
Nov 10
2025
|
Jack W Callicutt Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,291
+15.73%
|
$5,291
$1.44 P/Share
|
|
Nov 10
2025
|
Joel Lewis President and CEO |
SELL
Open market or private sale
|
Direct |
1,867
-0.22%
|
$11,202
$6.03 P/Share
|
|
Nov 10
2025
|
Joel Lewis President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,867
+0.22%
|
$3,734
$2.39 P/Share
|
|
Nov 05
2025
|
Joel Lewis President and CEO |
SELL
Open market or private sale
|
Direct |
200
-0.02%
|
$1,200
$6.0 P/Share
|
|
Nov 05
2025
|
Joel Lewis President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
200
+0.02%
|
$400
$2.39 P/Share
|
|
Nov 05
2025
|
Jack W Callicutt Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
600
-2.56%
|
$3,600
$6.0 P/Share
|
|
Nov 05
2025
|
Jack W Callicutt Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
600
+2.5%
|
$600
$1.6 P/Share
|
|
Nov 04
2025
|
Jack W Callicutt Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
28,629
-55.52%
|
$171,774
$6.07 P/Share
|
|
Nov 04
2025
|
Jack W Callicutt Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
28,629
+35.69%
|
$28,629
$1.6 P/Share
|
|
Nov 04
2025
|
Joel Lewis President and CEO |
SELL
Open market or private sale
|
Direct |
14,420
-1.7%
|
$86,520
$6.07 P/Share
|
|
Nov 04
2025
|
Joel Lewis President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
14,420
+1.67%
|
$28,840
$2.39 P/Share
|
|
Nov 03
2025
|
Jack W Callicutt Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,250
-14.1%
|
$7,500
$6.01 P/Share
|
|
Nov 03
2025
|
Jack W Callicutt Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,810
+12.51%
|
$3,810
$1.6 P/Share
|
|
Nov 03
2025
|
Jack W Callicutt Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,560
-14.39%
|
$15,360
$6.01 P/Share
|
|
Nov 03
2025
|
Joel Lewis President and CEO |
SELL
Open market or private sale
|
Direct |
1,300
-0.16%
|
$7,800
$6.01 P/Share
|
|
Nov 03
2025
|
Joel Lewis President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,300
+0.16%
|
$2,600
$2.39 P/Share
|
|
Oct 22
2025
|
10 X Fund, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
50,000
-0.42%
|
$200,000
$4.94 P/Share
|